Assembly Biosciences, Inc.
- ASMB
- NASDAQ
- Biotechnology
- Hepatitis B Therapeutics
$21.12
Today +4.77%Quote Oct 20, 2026, 04:55 PM UTC
−19.26%over the last month
Max drawdown −21.1%From 1-month high −20.8%3 months −23.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
73
Market value
$430.0M
Quote Oct 20
Floor
$18.98
10.1% below price
Resistance
$21.29
0.8% above price
Price vs analyst targets
11 analysts
Lowest target
$50.00Highest target
$53.00
$50.00Highest target
$53.00
- Price $21.12
- Average target $51.67
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 145% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ASMBPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free